Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Cyrus Therapeutics Inc. is currently managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter involves 1 distinct examiner and a distinct art unit. This indicates that the company's current prosecution efforts are focused on a single application within a specific technical classification.
The busiest examiner for this company is Rodriguez, Rayna B, who is currently handling 1 pending office action. Since this is the only active office action for the portfolio, Rodriguez, Rayna B is the sole official reviewing the company's work. For a patent practitioner, this means that the entire prosecution strategy is currently centered on the interactions with this distinct examiner.
The Biotechnology & Pharmaceuticals area is a complex field, but the company's current workload is limited to a single pending office action. This allows for a very targeted approach to the patent office, with all efforts directed toward a single art unit. The simplicity of this prosecution profile means that the applicant can focus entirely on the nuances of this one specific case.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RODRIGUEZ, RAYNA B | 1 | 33.6% | +19.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18684629 | SOS1 INHIBITOR AND USE THEREOF | RODRIGUEZ, RAYNA B | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18684629 | SOS1 INHIBITOR AND USE THEREOF | RODRIGUEZ, RAYNA B | — |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18684629 | SOS1 INHIBITOR AND USE THEREOF | RODRIGUEZ, RAYNA B | 1628 | §102§103 | Non-Final OA | — | Pending | Feb 16, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial